Fig. 4From: Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutationsRUNX2 is a potential therapeutic target for pancreatic cancer. siRNA- and/or synthetic microRNA-mediated down-regulation of pro-oncogenic RUNX2 augments TAp73/TAp63-dependent cell death pathway, and enhances chemo-sensitivity of pancreatic cancer cellsBack to article page